I'm LongbridgeAI, I can summarize articles.The Week
WuXi AppTec (2359.HK) fell 4.22% this week to close at HK$181.50, while the Hang Seng Index dropped 5.65%, meaning the stock outperformed the benchmark by about 1.43 percentage points. It was a week of fading strength: Monday opened at HK$186.60, touched a high of HK$195.30, and closed at HK$192.80. Tuesday pushed up to HK$195.20 before pulling back to HK$189.90. Wednesday was a narrow session at HK$188.30. Thursday saw the sharpest decline, sliding to an intraday low of HK$177.90 and ending at HK$181.50. Weekly amplitude was 9.32%, and average daily volume of 23.7m shares ran 11.61% above the 60-day median, pointing to heavier trading.
Key Events
Two voluntary announcements on Tuesday morning (17 November) both reported the dismissal of the 1260H litigation, removing a procedural overhang that had been hanging over the name. On Friday evening (20 November), two news items shifted focus back to the business: WuXi AppTec presented research platforms supporting its integrated CRDMO model, and the company guided 2026 chemistry revenue to RMB 52.8bn-53.5bn. The revenue range gives a concrete expectation for the segment, while the litigation dismissal early in the week provided a cleaner regulatory backdrop.
Analyst Ratings
Coverage is heavily skewed to the buy side: of 22 brokers, 18 have buy ratings and 4 have overweight, with no hold, underweight, or sell. The consensus rating is strong buy, with a consensus target of HK$238.46, about 31.38% above the latest close. Targets range from HK$215.385 to HK$277.426 — a spread of roughly HK$62 — but even the low end sits well above spot. The stock ranks 2nd among 12 names in the life sciences tools and services industry.
The Week Ahead
The main threads to follow are the chemistry revenue guidance and any residual procedural items after the litigation dismissal. The next scheduled event on the calendar is the FY2026 annual results disclosure on Monday, 15 March 2027, with estimated EPS of HK$9.8308 and estimated revenue of HK$72.6bn. In the coming weeks, the focus will be on whether the chemistry segment guidance is reinforced in regular updates.
In Short
The analyst picture is supportive — consensus target is more than 30% above spot and the industry ranking is near the top. Yet the stock faded after a strong start to the week, and the latest session’s capital flow showed large-lot money acting as a net seller. On valuation, the stock trades around 17.69x P/E and 4.85x P/B, neither stretched nor obviously cheap. What matters next is whether the revenue guidance gets followed through, and whether that large-lot selling persists.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
